Related Experiment Videos
Low dose thalidomide in patients with relapsed or refractory multiple myeloma
1Division of Haematology and Blood Coagulation, Department of Internal Medicine I, University of Vienna, Vienna, Austria.
Leukemia & Lymphoma
|January 24, 2004
Summary
Low-dose thalidomide demonstrates effectiveness and safety as rescue therapy for relapsing or refractory multiple myeloma. This approach offers a viable treatment option, potentially reducing adverse effects associated with higher doses.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Thalidomide shows promise in treating multiple myeloma.
- Previous studies escalated thalidomide doses, correlating adverse effects with intensity.
- Optimal thalidomide dosage for efficacy and safety remains undetermined.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose thalidomide in patients with relapsed or refractory multiple myeloma.
- To determine if lower thalidomide doses can achieve therapeutic effects with reduced toxicity.
Main Methods:
- A study involving 24 patients with relapsed (n=19) or refractory (n=5) multiple myeloma.
- Patients received low-dose thalidomide (median 100 mg/d, range 50-400 mg/d) as monotherapy or in combination with dexamethasone or VAD chemotherapy.
- Treatment regimens included thalidomide monotherapy (12 patients), thalidomide plus dexamethasone (8 patients), and VAD plus thalidomide (4 patients).
Main Results:
- An overall response was observed in 12 patients (50%).
- Responses varied by treatment: 42% with monotherapy, 63% with thalidomide-dexamethasone, and 50% with thalidomide-VAD.
- Treatment discontinuation due to side effects occurred in 3 patients; 1 patient died before assessment.
Conclusions:
- Low-dose thalidomide is an effective and safe rescue therapy for relapsing or refractory multiple myeloma.
- Response may be influenced by prognostic factors and tumor burden.
- Larger prospective studies are needed to confirm these findings and optimize treatment.